Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-0425 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GDC-0425 | DRUG | Oral escalating dose |
| gemcitabine | DRUG | Intravenous repeating dose |
Inclusion Criteria: * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1 * Signed Informed Consent Form * Histologically or cytologically documented, locally advanced or metastatic solid tumors or lymphoma for which standard therapy either does not exist or has...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GDC-0425 is an investigational small molecule being studied for the treatment of solid tumors. It is currently in Phase 1 clinical development, and the completed trial evaluated its safety, tolerability, and pharmacokinetics when administered with and without gemcitabine in patients with refractory solid tumors or lymphoma.
GDC-0425 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is an investigational small molecule in Phase 1 clinical development for the treatment of solid tumors.
GDC-0425 is in Phase 1 clinical development. The single trial for this drug, NCT01359696, has been completed. It is an investigational agent and has not been approved by regulatory authorities.
GDC-0425 has one completed Phase 1 trial, NCT01359696, which enrolled 40 patients with refractory solid tumors or lymphoma. The study evaluated the safety, tolerability, and pharmacokinetics of GDC-0425 administered with and without gemcitabine in the United States and France.
GDC-0425 is the primary name for this investigational small molecule being developed by Roche Holding AG. No alternative names have been reported for this drug in the available clinical trial information.